Astria Therapeutics Inc. Partners with Kaken Pharmaceutical for Phase 3 Development and Commercialization of Navenibart in Japan for Hereditary Angioedema

Reuters
08/06
<a href="https://laohu8.com/S/ATXS">Astria Therapeutics Inc</a>. Partners with Kaken Pharmaceutical for Phase 3 Development and Commercialization of Navenibart in Japan for Hereditary Angioedema

Astria Therapeutics, Inc., a biopharmaceutical company specializing in therapies for allergic and immunologic diseases, has entered into a licensing agreement with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of navenibart in Japan. Navenibart is a long-acting investigational monoclonal antibody inhibitor of plasma kallikrein, currently in Phase 3 development for the preventative treatment of hereditary angioedema $(HAE)$. Under the agreement, Astria will receive an upfront payment of $16 million, with potential additional commercialization and sales milestones totaling $16 million. The company is also eligible for tiered royalties based on net sales, reaching up to 30%, and will receive partial reimbursement for Phase 3 costs. Kaken will support the ALPHA-ORBIT Phase 3 trial, handle regulatory submissions in Japan, and share in the costs of the Phase 3 program. No results from the Phase 3 trial have been presented as of the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806414306) on August 06, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10